FDA
-
-
-
-
-
-
-
Novartis receives third FDA approval for oral Fabhalta
-
-
-
-
-
-
-
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
-
-
-
-
-
-
-
Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
-
-
-
-
-
-
-
Novan (NOVN) to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
-
-
-
-
-
-
-
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
-
-
-
-
-
-
-
Novan (NOVN) Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement
-
-
-
-
-
-
-
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
-
322,093 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

